Lucid Diagnostics Stock Shares Owned By Insiders
| LUCD Stock | USD 0.94 0.06 6.95% |
Lucid Diagnostics fundamentals help investors to digest information that contributes to Lucid Diagnostics' financial success or failures. It also enables traders to predict the movement of Lucid Stock. The fundamental analysis module provides a way to measure Lucid Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lucid Diagnostics stock.
Lucid | Shares Owned By Insiders |
Lucid Diagnostics Company Shares Owned By Insiders Analysis
Lucid Diagnostics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Lucid Diagnostics Shares Owned By Insiders | 70.39 % |
Most of Lucid Diagnostics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lucid Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lucid Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for Lucid Diagnostics is extremely important. It helps to project a fair market value of Lucid Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since Lucid Diagnostics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lucid Diagnostics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lucid Diagnostics' interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 70% of Lucid Diagnostics are shares owned by insiders. This is 363.69% higher than that of the Health Care Equipment & Supplies sector and notably higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Lucid Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lucid Diagnostics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lucid Diagnostics could also be used in its relative valuation, which is a method of valuing Lucid Diagnostics by comparing valuation metrics of similar companies.Lucid Diagnostics is currently under evaluation in shares owned by insiders category among related companies.
Lucid Fundamentals
| Return On Equity | -5.08 | ||||
| Return On Asset | -1.01 | ||||
| Operating Margin | (11.01) % | ||||
| Current Valuation | 56.47 M | ||||
| Shares Outstanding | 48.24 M | ||||
| Shares Owned By Insiders | 70.39 % | ||||
| Shares Owned By Institutions | 3.65 % | ||||
| Number Of Shares Shorted | 361.37 K | ||||
| Price To Book | 2.16 X | ||||
| Price To Sales | 16.07 X | ||||
| Revenue | 2.43 M | ||||
| Gross Profit | (3.24 M) | ||||
| EBITDA | (45.98 M) | ||||
| Net Income | (52.67 M) | ||||
| Cash And Equivalents | 34.46 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 15.26 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.55 X | ||||
| Book Value Per Share | (0.49) X | ||||
| Cash Flow From Operations | (32.82 M) | ||||
| Short Ratio | 1.23 X | ||||
| Earnings Per Share | (1.26) X | ||||
| Target Price | 3.83 | ||||
| Number Of Employees | 70 | ||||
| Beta | 1.63 | ||||
| Market Capitalization | 43.47 M | ||||
| Total Asset | 27.27 M | ||||
| Retained Earnings | (150.74 M) | ||||
| Working Capital | (7.31 M) | ||||
| Net Asset | 27.27 M |
About Lucid Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lucid Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lucid Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lucid Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Lucid Diagnostics Piotroski F Score and Lucid Diagnostics Altman Z Score analysis. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.Note that the Lucid Diagnostics information on this page should be used as a complementary analysis to other Lucid Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Lucid Stock analysis
When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Lucid Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.26) | Revenue Per Share 0.058 | Quarterly Revenue Growth 8.286 | Return On Assets (1.01) | Return On Equity (5.08) |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.